Journal of Clinical Oncology, Vol 15, 1427-1431, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma

KD Miller, PJ Loehrer, R Gonin and LH Einhorn
Department of Medicine, Indiana University Medical Center, Indianapolis 46202, USA.

PURPOSE: Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblastine, ifosfamide, and cisplatin (VeIP) will cure approximately 25% of patients. The purpose of this study was to evaluate the activity of VeIP in patients with recurrent seminoma. PATIENTS AND METHODS: We conducted a retrospective review of 24 patients with recurrent seminoma who were treated at Indiana University with VeIP as second-line chemotherapy. All patients had received cisplatin-containing regimens as primary chemotherapy and seven had also received prior pelvic radiotherapy. All patients received four courses of VeIP. RESULTS: The minimum follow-up duration was 2 years (range, 2 to 9.1), with a median follow-up time of 7 years. Twenty of 24 patients (83%) achieved a complete remission (CR) following VeIP alone. One additional patient was rendered disease-free (NED) with the resection of residual carcinoma. Eight patients have relapsed. Four of six patients with extragonadal primary tumors and two of four who failed to achieve CR with initial chemotherapy are continuously NED with VeIP. Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy. CONCLUSION: VeIP has significant curative potential in patients with recurrent seminoma and appears to produce a higher CR rate and more long-term survivors than is achieved in patients with nonseminomatous disease.

This article has been cited by other articles:

				A. Lorch, C. Kollmannsberger, J. T. Hartmann, B. Metzner, I. G.H. Schmidt-Wolf, W. E. Berdel, F. Weissinger, J. Schleicher, G. Egerer, A. Haas, et al. Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group J. Clin. Oncol., July 1, 2007; 25(19): 2778 - 2784. [Abstract] [Full Text] [PDF]

				G. Sonpavde, T. E. Hutson, and B. J. Roth Management of Recurrent Testicular Germ Cell Tumors Oncologist, January 1, 2007; 12(1): 51 - 61. [Abstract] [Full Text] [PDF]

				J. Oldenburg, J. M. Martin, and S. D. Fossa Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511. [Abstract] [Full Text] [PDF]

				S. Krege, C. Boergermann, R. Baschek, A. Hinke, T. Pottek, S. Kliesch, K.-P. Dieckmann, P. Albers, B. Knutzen, S. Weinknecht, et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG) Ann. Onc., February 1, 2006; 17(2): 276 - 280. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]

				D. Gholam, J.-P. Lotz, D. Atallah, and C. Theodore Germ Cell Tumors: CASE 2. Unusual Course of Pure Testicular Seminoma J. Clin. Oncol., May 1, 2004; 22(9): 1755 - 1756. [Full Text] [PDF]

				M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber, K. Oechsle, F. Sellner, A. Lang, K. Kletter, B. M. Dohmen, C. Dittrich, et al. 2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial J. Clin. Oncol., March 15, 2004; 22(6): 1034 - 1039. [Abstract] [Full Text] [PDF]

				D. W. George, R. S. Foster, R. A. Hromas, K. A. Robertson, G. H. Vance, T. M. Ulbright, T. A. Gobbett, D. J. Heiber, N. A. Heerema, H. C. Ramsey, et al. Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis J. Clin. Oncol., January 1, 2003; 21(1): 113 - 122. [Abstract] [Full Text] [PDF]

				J. Beyer, S. Stenning, A. Gerl, S. Fossa, and W. Siegert High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis Ann. Onc., April 1, 2002; 13(4): 599 - 605. [Abstract] [Full Text] [PDF]

				J. Vuky, S. K. Tickoo, J. Sheinfeld, J. Bacik, A. Amsterdam, M. Mazumdar, V. Reuter, D. F. Bajorin, G. J. Bosl, and R. J. Motzer Salvage Chemotherapy for Patients With Advanced Pure Seminoma J. Clin. Oncol., January 1, 2002; 20(1): 297 - 301. [Abstract] [Full Text] [PDF]

				M. De Santis, C. Bokemeyer, A. Becherer, F. Stoiber, K. Oechsle, K. Kletter, B. M. Dohmen, C. Dittrich, and J. Pont Predictive Impact of 2-18Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky Seminoma J. Clin. Oncol., September 1, 2001; 19(17): 3740 - 3744. [Abstract] [Full Text] [PDF]

				K. N. Ganjoo, R. J. Chan, M. Sharma, and L. H. Einhorn Positron Emission Tomography Scans in the Evaluation of Postchemotherapy Residual Masses in Patients With Seminoma J. Clin. Oncol., November 1, 1999; 17(11): 3457 - 3460. [Abstract] [Full Text] [PDF]